Novo Nordisk Files For Changes To Combination Limitations For GLP1 Receptor Agonist Victoza In Japan
This article was originally published in PharmAsia News
Executive Summary
Novo Nordisk has filed for partial changes to the efficacy of GLP-1 receptor agonist Victoza (liraglutide) in type 2 diabetes in Japan.